901 related articles for article (PubMed ID: 25973694)
1. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
2. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
3. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution, pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model.
Liu RS; Chou TK; Chang CH; Wu CY; Chang CW; Chang TJ; Wang SJ; Lin WJ; Wang HE
Nucl Med Biol; 2009 Apr; 36(3):305-12. PubMed ID: 19324276
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
7. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
9. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Stroobants S; Penninckx F; Haustermans K
Acta Oncol; 2008; 47(7):1237-48. PubMed ID: 18654902
[TBL] [Abstract][Full Text] [Related]
10. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
[TBL] [Abstract][Full Text] [Related]
11. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
[TBL] [Abstract][Full Text] [Related]
12. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
[TBL] [Abstract][Full Text] [Related]
13. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
van Waarde A; Cobben DC; Suurmeijer AJ; Maas B; Vaalburg W; de Vries EF; Jager PL; Hoekstra HJ; Elsinga PH
J Nucl Med; 2004 Apr; 45(4):695-700. PubMed ID: 15073267
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
16. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
17. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
Lu L; Jiang L; Guan H; Gao Y; Lu H
Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
[TBL] [Abstract][Full Text] [Related]
18. [Tumor targeting efficacy of a novel PET radiotracer (1)8F-AlF-NOTA-PRGD2 in mice].
Wu H; Wang Q; Han Y; Zhou W; Li H; Tian Y; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jan; 34(1):51-5. PubMed ID: 24463116
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
[TBL] [Abstract][Full Text] [Related]
20. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.
Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D
Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
